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Dmeasurement of these outcomes as well, not only in the
short term, but also in the intermediate and long term,
needs to be determined, because studies22,23 have shown
that patient-related and environmental factors are more
likely to contribute to neurodevelopmental outcomes in
specific subset of patients such as those undergoing the Nor-
wood stage I procedure and arterial switch operation.
Although this tool has been validated in 1 center for spe-
cific outcomes and specific subsets of patients, a multicenter
study is necessary to establish its reproducibility across
a wide range of diagnostic and procedural categories and
across a wide range of programs. The use of echocardiogra-
phy as the principle component of the TPS is advantageous,
because it is routinely obtained perioperatively and during
long-term follow-up in all centers. However, its disadvan-
tage is the variability in the interpretation of the findings.
We believe that standardization of the TPS modules will
allow for more uniform data collection.
CONCLUSIONS
The TPS, based on early operative results determined by
echocardiography at discharge and the need for early rein-
tervention to correct residual or recurrent defects, correlates
highly with both early- and intermediate-term outcomes.
The present study underscores the need for early assessment
of adequacy of the surgical procedure in addressing impor-
tant hemodynamic lesions and justifies an aggressive
approach to early intervention of residual defects.
We would like to acknowledge Kimberly Gauvreau, ScD, for
assistance with statistics, and Kathy Jenkins, MD, and the Program
for Patient Safety and Quality for pilot funding of this project.
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David M. Overman (Minneapolis, Minn). Meena, congratula-
tions on an excellent presentation and thank you for providing the
report well in advance of the meeting for review.
This work builds on a characteristically expansive foundation of
human factors research laid by Marc de Leval nearly 20 years ago.
Human factors are, of course, quite complex and difficult to
quantify. They include individual, technical, and organizational di-
mensions. Dr Bacha and his colleagues should be commended for
successfully filtering out 1 specific human factor, intraoperative
technical performance, and exploring its effect on outcomes
through a series of investigations now dating back to 2007.
The present study assesses the role of the TPS on late mortality
and unanticipated reintervention at a mean follow-up of 17
months. It extends the analysis of a prospective cohort of newbornsdiovascular Surgery c Volume 144, Number 5 1099
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Thoracic Surgery, a study that demonstrated the ability of techni-
cal performance to mitigate the effects of adverse intraoperative
events. The main findings of the present study are that the TPS
is strongly associated with late mortality or the need for transplan-
tation. Although this association is somewhat weaker when ad-
justed for age and complexity, it is particularly sobering to note
that survival at 2 years is a startling 50% among patients whose
TPS was inadequate.
Second, age and complexity did not correlate with late mortality
or the need for transplantation, although this is probably explained
by inadequate statistical power. The TPS is more weakly associ-
ated with late reintervention and in the report this association is
limited to non-neonates and patients with lower complexity.
Finally, on multivariate analysis, complexity alone was
associated with the need for late reintervention; notably, patients
requiring reintervention had a mortality rate of 15%.
I have 3 questions for the authors.
Number 1, it strikes me as counterintuitive that an inadequate
TPS does not significantly increase the risk of the need for reinter-
vention. The significant incidence of mortality among patients un-
dergoing reintervention and the strong association of TPS with late
mortality would seem to support a connection between TPS and
reintervention. Can you share with us more specific information
regarding the nature of these reinterventions, and does that data
offer any explanation for this apparent paradox?
Dr Nathan. I would like to bring to your attention that in the
initial cohort of 166 patients we had 7 early deaths, and most of
them, 6 of the 7 were in the high-risk category and were in
neonates, and 6 of the 7 had an inadequate technical performance.
Thus, if these patients had survived, the chances are that they
would have required multiple reinterventions or would have had
late deaths.
Unfortunately, our study was underpowered, because we only
had 159 patients. Also, if we had a larger subset of patients, we
probably could prove that inadequate TPSs would definitely be as-
sociated with the need for late reintervention, in addition to late
mortality.
DrOverman. Second, the TPS is based almost entirely on post-
operative echocardiographic assessment of residual disease. This
method has some potential weaknesses. One of these is that by
equating residual disease and technical performance, we introduce
confounding variables that impair the evaluation of technical per-
formance alone. For instance, what if the surgeon intentionally
leaves a residual gradient at the level of the pulmonary valve
during tetralogy repair, should that be considered technically
less than optimal? Should imperfect native anatomy really effect
TPS?
Dr Nathan. I agree that the TPS is not yet a perfect system, and
we are in the process of tweaking it, particularly for certain
diagnostic groups such as valve-sparing tetralogy repairs, valve
repairs, and, in fact, even for canal repairs, because often in canal
repairs, we accept trivial to mild regurgitation as acceptable, but
that would classify it as an adequate score, rather than an optimal
score.
We are in the process of modifying our TPS, and, hopefully,
after we have accrued enough data on each of these subgroups,
we might come up with a refined score.1100 The Journal of Thoracic and Cardiovascular SurDr Overman. Finally, we all know that one can perform a tech-
nically perfect operation but still lose the patient to the hazards of
the early postoperative environment, many of these hazards being
human factors. Have the authors considered study designs that at-
tempt measurement of other types of human factors, either alone or
combined with TPS and whether there any human factors you
would consider particularly important investigative targets for
those in the audience who might want to take up the baton?
Dr Nathan. I agree with the discussant that there are several
factors, in addition to technical performance, that will contribute
to the outcomes and a many of them are human factors, namely,
the cognitive factors, communication between the various teams
involved in the care of the patient, both intraoperatively and post-
operatively, and several other human factors that are closely inter-
related.We concentrated on the TPSs and, hopefully, oncewe have
refined it, we will study these other human factors, which we also
believe play an important part in outcomes.
Dr Overman. Thank you and congratulations on this work.
Dr V. Mohan Reddy (Stanford, Calif). Meena, I would like to
ask a question. I agree that technical performance is an important
factor in early and late outcomes, but the paper is so abstract when
you say ‘‘highly complex’’ and ‘‘interventions.’’ Can you tell me 1,
2, 3, in each category, what were the most complex diagnoses,
what were the 1, 2, 3 residual defects that required reintervention.
Dr Nathan. I have a list of the 55.
Dr Reddy. Just give me the top 3.
Dr Nathan. Most of them were pulmonary artery reinterven-
tions. Most of them, in the stage 1 and in the Tet groups, especially
the Tet pulmonary atresia MAPCAs, the other was arch interven-
tions, and the third was either redo valve repair or subaortic inter-
ventions in the canals.
Dr Reddy. So how many were single ventricle or is this
2-ventricle patients who participated?
DrNathan.About 50% to 60%were single ventricle. A number
of the reinterventions were in the single-ventricle group, which is
to be expected. Even when they had an optimal technical perfor-
mance, at their discharge echocardiogram, a number of them re-
quired reinterventions.
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
Dr Nathan, it is no secret I am a big fan of this work that you
have been pioneering. A couple questions.
One, I noticed on a couple of the slides, I think it was the late
interventions, and it might have even been early mortality, that
the ‘‘optimals’’ actually seemed to fare worse than the ‘‘ade-
quates.’’ I assume that was not statistically significant, but it was
a bit of a trend. Do you have any explanation for that? Because
it certainly would not have been expected.
Dr Nathan. The reason for that is a lot of the stage 1 cases, more
than 50%of the stage 1 cases, were in the optimal group, but a num-
ber required either arch reintervention or reintervention on their
shunts. We do have a very aggressive interventional cardiac pro-
gram; and during pre-bidirectional Glenn cardiac catheterization,
even if they see a minor arch gradient, they tend to balloon dilate,
and those patients were included in our reintervention group.
Also, a number of the adequate group belonged in the low-risk
RACHS category, namely, tetralogy of Fallot and canals; and, in
them, even an adequate technical score did not seem to require
late reintervention. Also, that might explain why the ‘‘adequates’’gery c November 2012
Nathan et al Congenital Heart Disease
C
H
Dseem to have done a little better in the various survival and reinter-
vention curves than the optimal patients.
Dr Caldarone. However, your first example was that some pa-
tients, for example Norwood, might have had an optimal outcome
in terms of the paradigm of the TPS but might have actually had
a lesion that required reintervention.
Dr Nathan. Yes. Not at discharge but developed that lesion
subsequently.
Dr Caldarone. Subsequently, I see.
Dr Nathan. Yes, they had an optimal score at discharge.
Dr Caldarone. So, presumably as your TPSs are modified and
calibrated to the patient populations, they will come more in line
with expectations and the prediction of reintervention.
Dr Nathan.Yes. We are in the process of accruing about 100 to
150 patients in each of these diagnoses so that we can further
modify the TPSs.
Dr Caldarone. Do you think you will be adding additional pa-
rameters to measure, or will you be redefining the cutpoints among
optimal, adequate, and inadequate?
Dr Nathan.We will initially redefine the cutpoints because we
find that what we classify as mild regurgitation on discharge echo-
cardiography in canals is often read as trivial on the follow-up
echocardiogram, even though the vena contracta appears the same.
So,wewill initially redefine the cutoff among optimal, adequate,
and inadequate and then we will consider weighting each of the
subcategories and procedures to determine which is more impor-
tant and is more likely to need reintervention or cause an adverse
outcome late during follow-up. For example, in a Norwood proce-
dure, is arch reobstruction more significant than a restrictive atrial
septum or a slightly narrow shunt? All of that needs to be redefined.
Dr Caldarone. So you redefine the cutpoints and add coeffi-
cients or weighting coefficients?
Dr Nathan. Yes.
Dr Marshall Jacobs (Newtown Square, Pa). I want to compli-
ment you as everyone has. We have followed this research with
great interest since the initial development of the tool. Also, oneThe Journal of Thoracic and Carof my recollections of your earlier reports of the short-term out-
comes and resource use is that the relationship between the TPS
and those measures varied between procedure groups, that there
are procedures for which suboptimal technical performance might
be associated with longer hospital stay or different measures of
outcome.
What you did in this study certainly makes sense. It is a very
logical next step. But, really, this was an example of lumping,
where the previous analyses were examples of splitting. Also,
you really only stratified the patients here by their theoretical com-
plexity as measured by RACHS, which is based on the estimated
risk of mortality. So I wonder, going forward, as you accrue
more data on more patients, as you have said you have to do,
whether it will not be most appropriate to consider these midterm
outcomes in relation to specific procedural groups.
I mean being left with a residual ventricular septal defect after
a ventricular septal defect repair has very different physiologic
consequences than being left with arch obstruction after aNorwood
operation. Also, the overall expectations of a suboptimal outcome
for 1 operation in terms of the survivability and functional status of
the patient are very different than the overall expectations of the
midterm outcomes for another operation.
So I compliment you on taking this to the next step, which was
a natural progression, but I think really to find insights into the
midterm associations with TPS, it is going to have to be broken
down into procedural groups, isn’t it?
DrNathan. I totally agreewith you, and we are in the process of
accruing these data. In our previous work on the initial presenta-
tion of 166 patients, we did show that an inadequate technical per-
formance in the high-risk group was associated with increased
mortality across all ranges. Thus, if you had an adequate technical
performance, you did well if you were low risk, but did poorly if
you were high risk. Also, if you had optimal technical perfor-
mance, you did relatively well in all risk categories. We agree
that considering specific procedures will give us a better insight
into what lesions need preemptive reintervention.diovascular Surgery c Volume 144, Number 5 1101
